The book is organized into 17 chapters, opening with study design and statistics, next describing the primary outcome analyses, then systematically moving through many domains of the study such as cost-effectiveness, psychosocial functioning, neurocognition, vocational and family outcomes, side effects, substance use, violence, and population pharmacokinetics, and concluding with implications for research design and practice and policy. True to the goal of representing something akin to an official record of CATIE, each chapter is complete and self-contained, including a brief overview of the relevant literature, study design and methods, results, and conclusions. Several chapters include data not published in the original articles on the given topic. Despite the large number of contributors to the volume, the format, tenor, and quality of the chapters are uniform. The only exception, perhaps unavoidable, is the chapter on genetic investigations, which appears incomplete and already outdated (i.e., there is barely a mention of the current lively debates around the relative contributions of common polymorphisms versus rare copy number variations to the pathogenesis of schizophrenia). There were two exceptions to the commendable effort at presenting thorough and complete information about CATIE: a list of members who served on the several CATIE-related committees (e.g., the Schizophrenia Protocol Development and Ancillary Study Committees) and the funds spent on CATIE (and perhaps some detail of how the monies were spent), both of which would have been nice to see in this volume.